Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
287.78 5.33   1.89%3,394,5782.1M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 7/22/2016

Latest News Headlines for Biogen Inc

( BIIB ) Post Earnings Coverage as Biogen Post 23% growth in EPS

LONDON, UK / ACCESSWIRE / July 22, 2016 / Active Wall St. announces its post-earnings coverage on Biogen Inc. (NASDAQ: BIIB). The company announced its Q2 FY16 financial results before the opening bell on Thursday, July 21, 2016. The biotech giant disclosed better-than-expected growth in its profits and revenues as sales were up on growth in its core multiple sclerosis (MS) drugs. The company also announced that Chief Executive George Scangos is stepping down. Additionally, the biopharmaceutical company upgraded its guidance for FY16 and unveiled a $5 billion share buyback program. Register with us now for your free membership at: http://www.activewallst.com/register/.

Biogen Reports Second Quarter 2016 Revenues of -5-

FUMADERM -- 23.2 23.2 -- 26.3 26.3 BENEPALI -- 17.2 17.2 -- -- -- -------- -------- -------- -------- -------- --------

Biogen Reports Second Quarter 2016 Revenues of -4-

value remeasurement of contingent consideration 10.6 2.3 (2.2) Hemophilia business separation costs 3.7 -- --

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

-6.06%
BIIB
Biogen Inc
-5.61%
Shire PLC (ADR)
-3.87%
Abbott Laboratories
-13.83%
Mylan NV
-16.62%
Teva Pharmaceutical Industries Ltd (ADR)
BIIB
Biogen Inc
0.00%
Shire PLC (ADR)
0.70%
Abbott Laboratories
2.41%
Mylan NV
0.00%
Teva Pharmaceutical Industries Ltd (ADR)
2.48%
BIIB
Biogen Inc
1.89%
Shire PLC (ADR)
0.02%
Abbott Laboratories
0.30%
-0.58%
Mylan NV
Teva Pharmaceutical Industries Ltd (ADR)
0.18%
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open282.09
Previous Close282.45
Day High290.92
Day Low281.3806
52 Week High7/22/2015 | 401.11
52 Week Low6/27/2016 | 223.0211
% Off 52 Week High-28.25%
% Off 52 Week Low29.04%
Beta (5 Yr)0.93
Volatility Avg7/22/2016 | 43.41
10-Day Avg. Volume2,109,461
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2016 | 17.13
P/E Ratio6/30/2016 | 16.8
Market CapLarge Cap | 63.1B
Shares Outstanding219.12M
Float218.4M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.49M
Short Ratio1.1
Short % of Float1.14%
As of 6/30/2016
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.